Nanofármacos

Pretomanid amorphous form

Resumen de: AU2026201552A1

Abstract The present invention relates to pretomanid in amorphous form. The invention also relates to method of using the same, such as in a method of treating a mycobacterial infection. eb e b

Alginate-based microcapsulation for the delivery of alpha-CGRP in cardiovascular diseases

Resumen de: AU2026201537A1

Methods and systems for delivering a very potent vasodilator that has the ability to treat and prevent heart failure including delivering microcapsules containing α-CGRP, which show no toxicity and lowers blood pressure similar to the native peptide, where this new compound could greatly enhance the lifespan 5 of patients suffering from heart failure. eb e b

POLYPROLINE-BASED BLOCK COPOLYMERS

Resumen de: WO2025003463A1

The present invention relates to polyproline-based block copolymers and compositions thereof, which e.g. are useful for delivering active ingredients, including nucleic acids, and/or imaging agents to target cells or tissues.

EXTRACELLULAR VESICLES FOR THE DELIVERY OF PAYLOADS TO EUKARYOTIC CELLS

Resumen de: AU2024267555A1

The invention relates to the production, modification, and use of extracellular vesicles (EVs), particularly for the delivery of payloads of nucleic acids. The EVs can contain retroviral capsids and can be coated with polymers. The EVs can be treated with a protease to remove proteins on the outer surface of the EV to create shaved EVs. The shaved EVs can be coated with a polymer and used for the delivery of payloads of nucleic acids to cells.

NANOPARTICLES FOR TRANSPORTING ACTIVE SUBSTANCES COMPRISING ANIONIC GROUPS, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF

Resumen de: WO2024235481A1

The invention relates to lipid nanoparticles containing selected quantities of a) at least one cationic lipid, b) at least one phospholipid, and c) at least one selected stealth lipid, with the proviso that all the lipids contained in the lipid nanoparticle have an HLB value of greater than or equal to 3. These nanoparticles can be charged with active substances containing anionic groups, preferably with nucleic acids, and are suitable as highly efficient vehicles for transferring nucleic acids into cells.

TRANSFECTION COMPLEXES AND METHODS OF USING THE SAME

Resumen de: EP4710943A2

Disclosed herein are transfection complexes comprising at least one cell surface ligand; at least one helper lipid component; and a transfection enhancer. Also disclosed are pharmaceutical compositions comprising the disclosed transfection complexes, and a pharmaceutically acceptable carrier. Further, disclosed are methods of transfecting a cell, the method comprising the steps of: obtaining a transfection complex as disclosed; and contacting a cell with the transfection complex.

CATIONIC LIPIDS AND PREPARATION METHOD THEREOF

Resumen de: US20260069542A1

The present invention provides cationic lipids and lipid nanoparticle formulations comprising these lipids, alone or in combination with other lipids. These lipid nanoparticles may be formulated with nucleic acids to facilitate their intracellular delivery both in vitro and for therapeutic applications. The present invention also provides methods of chemical synthesis of these lipids.

EXTRACELLULAR VESICLE COMPOSITIONS AND PREPARATION

Resumen de: CN121335693A

In various aspects and embodiments, compositions containing extracellular vesicles, including modified extracellular vesicles, methods of making formulations of extracellular vesicles, methods of modifying extracellular vesicles, and methods of using modified and/or unmodified extracellular vesicles are provided.

IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY

Resumen de: MX2025013363A

The present disclosure describes compounds of Formula (I) and pharmaceutically acceptable salts thereof:

PREPARATION FOR SIRNA AND DRUG CO-DELIVERY SYSTEM FOR EFFICIENTLY TARGETING GLIOMA INITIATING CELLS, AND USE

Resumen de: EP4710942A1

Preparation for an siRNA and drug co-delivery system for efficiently targeting glioma initiating cells, and a use; ^DVAP targeting peptide modification is performed on exosomes by utilizing a click chemistry method, siRNA and mitoxantrone are loaded into the exosomes, and construction is performed to obtain a target-modified drug carrier exosome ^DVAP-Exo/siRNA/MIT. The target-modified exosome co-carries chemotherapeutic mitoxantrone, which has a strong killing effect on glioma initiating cells and can trigger immunogenic cell death, and a small interfering nucleic acid (siNotch 1), which is capable of reducing glioma initiating cell stemness; targeted tracking and killing of residual glioma initiating cells and tumor cells are achieved, and a new avenue is provided for glioblastoma treatment.

A COMPOUND FOR PREPARING LIPID NANOPARTICLES ENCAPSULATING AN AGENT, NANOPARTICLE COMPOSITION COMPRISING SAID COMPOUND AND RELATED METHODS THEREOF

Resumen de: CN121175037A

Provided is a compound represented by general formula (1) for preparing lipid nanoparticles encapsulating therapeutic, prophylactic and/or biological agents;

COMBINATIONS OF NANOPARTICLE-LOADED IMMUNE AGONISTS AND RAS TARGETED THERAPIES FOR TREATMENT OF CANCER

Resumen de: WO2024238486A2

Described herein is the combination of STING/TLR4 agonist nanoparticles (NPs) and a combination of a MEK inhibitor (e.g., trametinib) and CDK4/6 inhibitor (e.g., palbociclib) treatment. This combination synergizes to (a) lead to enhanced NP uptake in multiple cell types in the TME, (b) increased antigen presentation on tumors cells as well as APCs, and (c) CD8+ T cell mediated long-term tumor control that is interferon signaling dependent. Also provided are methods to treat cancer, e.g., KRAS mutant cancers, e.g., KRAS mutant PDAC or lung cancer.

猫疱疹病毒环状RNA疫苗及其应用

Resumen de: CN121674437A

本申请公开了一种猫疱疹病毒环状RNA疫苗及其应用。所述环状RNA疫苗是通过对猫疱疹病毒1型（FHV‑1）的四种糖蛋白gB、gD、gE、gI进行了系统性的抗原优化，并在此基础上构建了融合蛋白，实现了多抗原的协同免疫；进而基于这些优化的抗原及融合蛋白，制备了环状RNA疫苗。较之现有技术，本申请实现了更安全、更稳定、免疫效果更持久的猫用病毒疫苗的开发和生产，工艺稳定、可靠，可实现高质量疫苗产品的规模化生产。

一种纳米粒交联水凝胶及其应用

Resumen de: CN121668090A

本发明公开了一种纳米粒交联水凝胶及其应用，该纳米粒交联水凝胶由端基功能化的纳米粒和侧链功能化修饰的亲水性高分子材料制成，由于硫醇基团和不饱和双键基团可通过迈克尔加成反应进行连接，因此选择硫醇基团和不饱和双键基团形成纳米粒和亲水性高分子材料的连接键从而实现水凝胶成型。本发明以纳米粒为交联剂的水凝胶递送系统，通过纳米粒与水凝胶的双重装载策略，实现了多种药物的装载与递送。

负载布地奈德的人参囊泡递送系统及其构建方法和应用

Resumen de: CN121668137A

本发明公开了植物来源纳米药物递送系统技术领域的负载布地奈德的人参囊泡递送系统及其构建方法和应用。该递送系统以人参来源的纳米囊泡为载体，包载布地奈德形成BUD@GDNPs复合物。该递送系统可协同增强布地奈德的抗炎效果，显著减轻哮喘模型动物的气道炎症，同时降低高剂量布地奈德引发的血糖紊乱等副作用，生物安全性优异。本发明提供的递送系统可用于哮喘的临床治疗，尤其适用于需要长期使用糖皮质激素的患者，解决了传统布地奈德生物利用度低、副作用明显的技术难题，具有重要的临床应用价值和产业化前景。

一种用于治疗心肌梗死的纳米药物递送系统及其制备方法与应用

Resumen de: CN121668131A

本发明涉及一种用于治疗心肌梗死的纳米药物递送系统，包括：锰硒纳米颗粒、包覆于所述锰硒纳米颗粒的外表面上的聚多巴胺层、以及包裹于所述聚多巴胺层的外表面上的M1型巨噬细胞来源的外泌体膜。本发明的纳米药物递送系统静脉注射后可在梗死区高度富集并长时间停留，显著缩减梗死面积，左室收缩与舒张功能同步改善，心室异常重构得到抑制，药物向肝脾的被动分布相应减少。

CES1/CES2级联激活的喜树碱-脂肪醇前药和其白蛋白纳米粒以及其制备方法和应用

Resumen de: CN121673291A

本发明涉及CES1/CES2级联激活的喜树碱‑脂肪醇前药和其白蛋白纳米粒以及其制备方法和应用，属于医药技术领域。该CES1/CES2级联激活的喜树碱‑脂肪醇前药，其是式(I)所示的前药或其药学上可接受的盐。本发明还涉及包载CES1/CES2级联激活的喜树碱‑脂肪醇前药制备的结合型白蛋白纳米粒。该白蛋白纳米粒的粒径较小且形态均一，具有良好的放置稳定性和胶体稳定性，在体循环和正常组织中均能稳定存在，但被肿瘤细胞摄取后，经过CES1介导的初级水解释放出中间体，随后中间体在CES2的作用下发生次级水解而释放出母药喜树碱，从而实现特异性杀伤肿瘤细胞而不产生严重的毒副作用，具有良好的临床开发前景。式(I)

一种I型光动力脂质体反应器的制备方法及应用

Resumen de: CN121668305A

本发明公开了一种I型光动力脂质体反应器的制备方法及应用，属于生物医药技术领域。本发明将此光敏剂、磷脂、胆固醇和DSPE‑mPEG、DSPE‑mPEG‑Biotin、DSPE‑mPEG‑Gal通过特定方式混合组装，得到脂质体反应器TGoE@BG‑Lipo。并基于该脂质体反应器提供一种肝肿瘤靶向的纳米治疗药物。本发明肝肿瘤靶向的治疗药物具有较好的稳定性及能被肿瘤微环境触发药物释放，能够发挥I型光动力治疗、化疗和饥饿治疗的多模式治疗；此外，在皮下缺氧实体瘤模型中发挥了良好的治疗功效，有望应用于临床研究。

一种用于预防猫传染性腹膜炎的广谱mRNA疫苗及其制备方法

Resumen de: CN121668297A

本发明提供了一种用于预防猫传染性腹膜炎的广谱mRNA疫苗及其制备方法，该疫苗包含mRNA分子1和mRNA分子2，mRNA分子1包含基于串联FIPV I型S蛋白的中和表位与T细胞表位的自组装LS纳米颗粒融合序列，以及N蛋白和M蛋白的抗原编码序列组成的LS‑FIPV‑I MEV‑N‑M抗原蛋白编码序列；mRNA分子2包含由FIPV II型S蛋白受体结构域RBD融合自组装的LS纳米颗粒结构的抗原蛋白编码序列。本发明通过双mRNA分子组合，可在规避ADE风险的同时，实现对FIPV I型和II型的广谱保护。

一种聚多巴胺修饰的钴单原子纳米酶体系及其制备方法、应用

Resumen de: CN121668136A

本发明提供了一种聚多巴胺修饰的钴单原子纳米酶体系，包括钴单原子纳米酶以及包覆在钴单原子纳米酶表面的聚多巴胺包覆层；所述钴单原子纳米酶由前驱体Co@MOF@SiO2经热解和刻蚀后得到。本发明中Co SA具备类过氧化氢酶与类超氧化物歧化酶活性，能精准调控酒精诱导的氧化应激及炎症反应通路；PDA依托生物粘附性实现Co SA在胃部的有效滞留，并凭借良好生物相容性提升应用的安全性。该体系可通过激活NRF2信号通路并抑制NF‑κB信号通路增强组织抗氧化能力并阻断炎症级联反应，显著减轻酒精引发的胃黏膜损伤与肝脏病变，改善氧化应激及炎症反应。本发明为酒精性胃炎与肝炎的同步联合防治提供了方向及实验依据。

用于肿瘤化疗、免疫联合治疗的纳米颗粒及其制备方法与应用

Resumen de: CN121668135A

本发明公开了用于肿瘤化疗、免疫联合治疗的纳米颗粒及其制备方法与应用，属于生物医药技术领域。所述纳米颗粒为重组人重链铁蛋白（rHF）包裹雷公藤红素（Cel）形成的rHF@Cel纳米颗粒。其制备方法包括：获得重组rHF蛋白，将Cel与rHF在特定pH和温度条件下混合组装，纯化后即得。该纳米颗粒能有效靶向肿瘤细胞，释放Cel杀伤肿瘤；同时，rHF载体能诱导肿瘤相关巨噬细胞由促肿瘤的M2型向抗肿瘤的M1型极化，并降低肿瘤微环境中调节性T细胞（Treg）的比例，逆转免疫抑制微环境。体外和体内实验证明，rHF@Cel纳米颗粒对乳腺癌细胞具有显著杀伤作用，并能有效抑制小鼠移植瘤的生长。

一种肿瘤-细菌膜嵌合的纳米颗粒的制备方法及其应用

Resumen de: CN121668132A

本发明涉及抗肿瘤仿生纳米材料技术领域，公开了一种肿瘤‑细菌膜嵌合的纳米颗粒的制备方法及其应用，包括：将二肉豆蔻酰磷脂酰胆碱和胆固醇油酸酯旋转蒸发得到HDL旋蒸薄膜；将肿瘤细胞膜与细菌膜混合得到肿瘤‑细菌混合膜；将载脂蛋白ApoA‑1与该肿瘤‑细菌混合膜预混合，再将混合溶液加入含HDL旋蒸薄膜的容器中水化重构，得到粗品悬液；将粗品悬液超滤纯化，得到肿瘤‑细菌膜嵌合的纳米颗粒。本发明通过将肿瘤细胞膜与细菌膜共载于高密度脂蛋白上，能够将两种膜组分共递送至树突状细胞以诱导其成熟，并在体内蓄积于肿瘤及引流淋巴结，激活CD8+T细胞应答，对肿瘤生长产生抑制作用。

一种UTR元件Hh及其构建方法和应用

Resumen de: CN121674402A

本发明提供一种UTR元件Hh及其构建方法和应用，涉及mRNA技术领域。通过PaddleHelix平台对NCBI编号为AF339412.1的基因的5'UTR和NCBI编号为MK475748.1的基因的5'UTR分别进行核糖体载量预测和二级结构优化，获得的优化序列避免了抑制性发夹结构，使荧光素酶表达量较天然UTR明显提升。在优化序列基础上通过分子克隆技术将HBB与hbb进行定向组装，构建形成HBB‑hbb嵌合体（Hh），Hh的DNA序列如SEQ NO.1所示，RNA序列如SEQ NO.2所示，使蛋白表达量进一步提升。

一种氧化还原敏感型阳离子聚合物基因载体及其制备与应用

Resumen de: CN121668327A

本发明公开了一种氧化还原敏感型阳离子聚合物基因载体及其制备与应用。本发明采用带有氧化/还原响应性S‑S键的疏水小分子对聚缩水甘油胺进行侧链修饰，制备得到具有特异性肿瘤微环境响应能力的阳离子聚合物基因递送载体材料。该材料具有良好的生物相容性，能够有效负载siRNA分子并形成具有良好稳定性和优异基因转染能力的siRNA复合物纳米粒子。该复合物纳米粒子能够被细胞有效摄取，并且可以有效响应氧化/还原肿瘤微环境，实现siRNA的靶向释放。本发明提供的氧化/还原响应阳离子聚合物基因载体具有较大的临床应用前景。

一种近红外二区聚集诱导发光材料及其制备方法与在制备I型光动力药物中的应用

Nº publicación: CN121673299A 17/03/2026

Solicitante:

香港中文大学（深圳）

Resumen de: CN121673299A

本发明提出了一种近红外二区聚集诱导发光材料及其制备方法与在制备I型光动力药物中的应用，属于生物医学工程技术领域。以本发明得到的近红外二区聚集诱导发光材料作为给体，以硫杂萘二酰亚胺作为受体，通过泊洛沙姆F127将给体与受体整合构建得到一种NDA/BA纳米颗粒，进一步用于制备I型光动力药物中。该NDA/BA纳米颗粒展现出显著增强的I型光动力性能，其总活性氧、·OH和O2·‑生成量显著提高，并证实其具有精准的近红外二区成像与光动力治疗效果，为近红外二区影像引导的光动力诊疗一体化提供了前景广阔的新方案。